Study of mepolizumab safety syringe in asthmatics

Trial Identifier: 205667
Sponsor: GlaxoSmithKline
NCTID:: NCT03021304
Start Date: February 2017
Primary Completion Date: August 2017
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Canada, Québec Sainte-Foy, Québec, Canada, G1V 4G5
Canada, Québec St. Charles-Borromee, Québec, Canada, J6E 2B4
Netherlands AMSTERDAM, Netherlands, 1105 AZ
Netherlands LEEUWARDEN, Netherlands, 8934 AD
Netherlands ZWOLLE, Netherlands, 8025 AB
Russian Federation Ekaterinburg, Russian Federation, 620109
Russian Federation Moscow, Russian Federation, 123095
Russian Federation Saint-Petersburg, Russian Federation, 198328
Sweden LINKÖPING, Sweden, SE-581 85
Sweden LUND, Sweden, SE-221 85
Sweden STOCKHOLM, Sweden, SE-141 86
United States, Alabama Birmingham, Alabama, United States, 35243
United States, California Los Angeles, California, United States, 90025
United States, Ohio Cincinnati, Ohio, United States, 45231
United States, South Carolina Orangeburg, South Carolina, United States, 29118-2040